Denmark Sweden Norway Finland  Genzyme Danmark HomeKontaktGenzyme Corporate Home
OM OS
BEHANDLINGSOMRÅDER
PRODUKTER
Genzyme  
Genzyme er ét af verdens førende bioteknologiske firmaer og vores mål, er at forbedre livet for patienter med alvorlige sygdomme. Læs mere her
 
NYHEDER
PRESSEMEDDELSE
Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients


CAMBRIDGE, Mass. --Genzyme, a Sanofi company, announced today that the first pediatric patient has begun treatment in a Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa. Olipudase alfa is an enzyme replacement therapy being studied for the treatment of nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological involvement. ASMD is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase (ASM) resulting in toxic accumulation of sphingomyelin. There are currently no approved treatment options for patients with Niemann-Pick disease type B.
Mere >

genzyme i
norden
genzyme
biosurgery
genzyme
corporation
 

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster